TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3309752
Drug: Meclofenamate (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meclofenamate (single dose)
Study: 27717113
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months healing time before implant placement
Study: 27717113
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months healing time before implant placement
Study: 25560227
Drug: 6× weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6× weekly in-center hemodialysis (frequent HD)
Study: 25560227
Drug: 6× weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6× weekly nocturnal hemodialysis (frequent HD)
Study: 25560227
Drug: 3× weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3× weekly hemodialysis (conventional HD)
Study: 21706221
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Divalproex sodium (up to 1,500 mg/day)
Study: 21706221
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Divalproex sodium (up to 250 mg/day)
Study: 18448393
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of primary and secondary prevention
Study: 14550900
Drug: nalbuphine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine (2.5 mg) with naloxone (0.2 mg)
Study: 14550900
Drug: nalbuphine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine (2.5 mg)
Study: 14550900
Drug: nalbuphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine (5 mg) with naloxone (0.4 mg)
Study: 14550900
Drug: nalbuphine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine (2.5 mg) with naloxone (0.4 mg)
Study: 8693548
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine microemulsion (mean dose: 5.9 mg/kg/day, range: 3.0‐11.7 mg/kg/day)
Study: 8693548
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine microemulsion
Study: 1860215
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg, alternate-day)
Study: 23126676
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy under the Watt's protocol with adaptation to Chinese Culture (six weekly sessions of 90 minutes each)
Study: 20546160
Drug: Inhaled sevoflurane
Normalized name: sevoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sevoflurane (IS)
Study: 18184957
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg intravenous every 6 hours for 5 days, then tapered over 6 days)
Study: 18184957
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered every 6 hours for 5 days, then tapered over 6 days)
Study: 8643424
Drug: sCT (Miacalcic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCT (Miacalcic, Sandoz, nasal spray, 2 x 100 IU/day)
Study: 8643424
Drug: sCT as
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCT as the first active drug
Study: 343181
Drug: PGE2‐analogue SHB
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2‐analogue SHB 286 (50‐200 microgram extravular dose)
Study: 343181
Drug: PGE2‐analogue SHB
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2‐analogue SHB 286 (1000‐2000 microgram intravenous infusion)
Study: 28885566
Drug: Cinnamon supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon supplement (3 g/day)
Study: 23374027
Drug: BTDS 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTDS 20 μg/h (Butrans®)
Study: 23374027
Drug: BTDS 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTDS 5 μg/h (Butrans®)
Study: 19329221
Drug: Docetaxel 40
Normalized name: docetaxel 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8 every 21 days (arm A)
Study: 19329221
Drug: Docetaxel 50
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 50 mg/m² days 1 and 15 plus gemcitabine 1600 mg/m² days 1 and 15 every 28 days (arm B)
Study: 19329221
Drug: Gemcitabine 1200
Normalized name: gemcitabine 1200 MG in 120 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1200 mg/m² days 1 and 8 plus cisplatin 100 mg/m² day 2 every 21 days for 3 cycles followed by docetaxel 75 mg/m² day 1 every 21 days for 3 cycles (arm C)
Study: 11590384
Drug: Inhaled steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroid (440 microg fluticasone propionate [FP] twice per day)
Study: 8724019
Drug: Hyperglycaemia (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia (blood glucose approximately equal to 15 mmol/l)
Study: 30375104
Drug: Patches
Normalized name: Provent Hemp Patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patches
Study: 30375104
Drug: Manual Pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Pressure Augmentation (MPA)
Study: 19443246
Drug: Roland disability
Normalized name: Recombinant human rod-derived cone viability factor
DrugBank: FOV 2501 (DB17886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roland disability questionnaire (RDQ) administered at T1 and T2
Study: 18188743
Drug: Nicotine craving,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine craving, withdrawal symptoms, and smoking urges measured daily for 30 days post-quit date.
Study: 15933856
Drug: Dynamic exercise
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic exercise therapy
Study: 11034583
Drug: SB-207266 (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-207266 (0.5, 5, and 20 mg doses)
Study: 11034583
Drug: SB-207266 (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-207266 (0.05, 0.5, or 5 mg)
Study: 8543503
Drug: Meropenem (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (10 to 20 mg/kg every 8 h)
Study: 8543503
Drug: Cefotaxime (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (100 to 150 mg/kg/day), with or without amikacin or metronidazole
Study: 2116610
Drug: GnRH-a (leuprolide
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH-a (leuprolide acetate depot 3.75 mg every 28 days)
Study: 28566400
Drug: Arthroscopic acromioplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic acromioplasty and supervised exercise treatment
Study: 28566400
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise treatment alone
Study: 26400874
Drug: Nighttime dosing
Normalized name: Flonase Nighttime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nighttime dosing of antihypertensive medications
Study: 23755867
Drug: Ivabradine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 2.5 mg
Study: 23755867
Drug: Ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 5 mg
Study: 23755867
Drug: Ivabradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 10 mg
Study: 19138567
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (thioridazine, chlorpromazine, haloperidol, trifluoperazine, or risperidone) for 12 months
Study: 19138567
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (thioridazine, chlorpromazine, haloperazine, trifluoperazine, or risperidone) for 12 months
Study: 19138567
Drug: Antipsychotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic treatment (thioridazine, chlorpromazine, haloperidone, trifluoperazine, or risperidone) for 12 months
Study: 18236771
Drug: Tailored psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored psychosocial and biological interventions
Study: 7819171
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Latanoprost and Timolol
Study: 7819171
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Timolol and Latanoprost
Study: 31841417
Drug: Error Augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Error Augmentation (EA) in immersive VR
Study: 31841417
Drug: Training without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Training without Error Augmentation (EA)
Study: 25398701
Drug: Anti-arrhythmic medication
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-arrhythmic medication
Study: 25398701
Drug: Non-selective beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-selective beta-blocker
Study: 25398701
Drug: Other cardiovascular
Normalized name: INVESTIGATIONAL OTHER CARDIOVASCULAR DISEASES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other cardiovascular and psychotropic medication
Study: 15321262
Drug: sufentanil 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil 7.5 microg (1.5 ml)
Study: 15321262
Drug: sufentanil 5
Normalized name: SUFentanil 50 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil 5 microg + bupivacaine 1 mg (1.5 ml)
Study: 15321262
Drug: bupivacaine 1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 1.75 mg, sufentanil 1.05 microg and epinephrine 1.75 microg (1.5 ml)
Study: 30636281
Drug: Gabapentin 800
Normalized name: gabapentin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 800 mg (Neurontin)
Study: 30636281
Drug: Gabapentin 800
Normalized name: gabapentin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 800 mg (Gabasandoz)
Study: 29049611
Drug: Prophylactic up‐front
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic up‐front surgery within 6 months from diagnosis combined with oncologic treatment
Study: 29049611
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment or delayed surgery as needed combined with oncologic treatment
Study: 22253270
Drug: Remimazolam (0.01-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (0.01-0.3 mg/kg)
Study: 22253270
Drug: Remimazolam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remimazolam (6 mg initial loading dose followed by 3 mg maintenance doses)
Study: 15728298
Drug: CoQ10 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (3 x 100 mg/day)
Study: 9807845
Drug: Tramadol HCl
Normalized name: tramadol HCl
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol HCl 1.5 mg/kg
Study: 7665860
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (Cefotaxime + Metronidazole)
Study: 28035736
Drug: Whole-grain rye
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain rye porridges (40 g)
Study: 28035736
Drug: Whole-grain rye
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain rye porridges (55 g)
Study: 28035736
Drug: Rye porridge
Normalized name: Rye
DrugBank: Rye (DB10564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rye porridge enriched with inulin: gluten proportions (9:3 g)
Study: 28035736
Drug: Rye porridge
Normalized name: Rye
DrugBank: Rye (DB10564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rye porridge enriched with inulin: gluten proportions (6:6 g)
Study: 28035736
Drug: Rye porridge
Normalized name: Rye
DrugBank: Rye (DB10564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rye porridge enriched with inulin: gluten proportions (3:9 g)
Study: 28035736
Drug: Refined wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined wheat bread (control, 55 g)
Study: 25660206
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion to sleep deeper before a midday nap
Study: 23257734
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate 20 mg
Study: 18805963
Drug: Recombinant asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant asparaginase preparation
Study: 16407508
Drug: Benazepril 20
Normalized name: benazepril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 20 mg per day (group 1)
Study: 16407508
Drug: Benazepril 20
Normalized name: benazepril 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 20 mg per day (group 2)
Study: 1505913
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (13 to 15 mg/kg body wt/day)
Study: 22435936
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment group
Study: 1375684
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no inotropic therapy)
Study: 3965373
Drug: Retinyl acetate
Normalized name: RETINYL ACETATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl acetate (RA) gel 3 mg
Study: 3965373
Drug: Retinyl acetate
Normalized name: RETINYL ACETATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl acetate (RA) gel 6 mg
Study: 3965373
Drug: Retinyl acetate
Normalized name: RETINYL ACETATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl acetate (RA) gel 9 mg
Study: 3965373
Drug: Retinyl acetate
Normalized name: RETINYL ACETATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl acetate (RA) gel 18 mg
Study: 29575006
Drug: Molidustat 50
Normalized name: Molidustat
DrugBank: Molidustat (DB15642)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Molidustat 50 mg
Study: 29575006
Drug: Molidustat (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molidustat (doses of 12.5 mg and above)
Study: 29575006
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of molidustat
Study: 26442829
Drug: TAC level(t)
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC level(t) <4.0 ng/ml
Study: 26442829
Drug: TAC level(t)
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC level(t) ≥4.0 ng/ml
Study: 24580383
Drug: Epidural 0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural 0.75% levobupivacaine 12 ml with 1 ml (0.5 µg/kg) of dexmedetomidine
Study: 24580383
Drug: Epidural 0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural 0.75% levobupivacaine 12 ml with 1 ml of isotonic sodium chloride solution
Study: 16697169
Drug: Lipidic physical
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipidic physical blend formulation (PB)
Study: 12800415
Drug: Manshuailing Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manshuailing Oral Liquid (MSL) 100 ml, 2 times a day for 4 months
Study: 12800415
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with western drugs (cardiotonic, diuretic, coronary dilator, etc.)
Study: 12800415
Drug: Manshuailing Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manshuailing Oral Liquid (MSL) in patients with mixed heart failure (systolic and diastolic dysfunction)
Study: 11193499
Drug: Intertrochanteric hip
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intertrochanteric hip fracture treatment
Study: 9004441
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg GMDP
Study: 9004441
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg GMDP
Study: 9004441
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg GMDP
Study: 9004441
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg GMDP
Study: 29420997
Drug: l-carnosine 500
Normalized name: L-Carnosine
DrugBank: Carnosine (DB11695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnosine 500 mg (2 capsules)
Study: 20660002
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs (medical treatment)
Study: 20660002
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with TAO (regardless of treatment)
Study: 18822620
Drug: Teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide 20 microg daily subcutaneously
Study: 7560219
Drug: Triclosan pre-treatment
Normalized name: Triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triclosan pre-treatment before histamine application
Study: 7012995
Drug: Bacampicillin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin (800 mg twice daily for 14 days)
Study: 7012995
Drug: Ampicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (500 mg four times daily for 14 days)
Study: 31522159
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) at a dose of 70 mg once weekly for six months plus local debridement
Study: 31522159
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of LS (1 gm tid for six weeks) and ALN (70 mg once weekly for six months) plus local debridement
Study: 21239867
Drug: E170 insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: E170 insulin assay
Study: 21239867
Drug: Measurement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurement of free insulin after PEG pre-treatment
Study: 12938815
Drug: Galantamine 24
Normalized name: galantamine 24 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 24 mg per day
Study: 10993031
Drug: HRT alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT alone (micronized E2 0.5 mg + micronized P4 100 mg)
Study: 10993031
Drug: HRT +
Normalized name: Hormone Replacement Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT + T (micronized E2 0.5 mg + micronized P4 100 mcg + micronized T 1.25 mg)
Study: 3909323
Drug: Aztreonam (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (1-g or 2-g intravenous doses, three times daily for at least five days)
Study: 3909323
Drug: Tobramycin (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (administered to a group of 34 patients)
Study: 29415754
Drug: Guanxinning tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanxinning tablet (GXNT) plus aspirin for 12 months
Study: 29415754
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone for 12 months
Study: 29415754
Drug: Guanxinning tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanxinning tablet (GXNT) plus aspirin
Study: 25399975
Drug: Danhong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong Injection
Study: 23597225
Drug: APF (1.23%
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF (1.23% acidulated phosphate fluoride gel)
Study: 23597225
Drug: NNaF (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNaF (2% neutral sodium fluoride gel)
Study: 16734505
Drug: Calcipotriene cream
Normalized name: Calcipotriene Cream
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene cream group
Study: 16734505
Drug: Calcipotriene cream
Normalized name: Calcipotriene Cream
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene cream vs Vehicle
Study: 16734505
Drug: Calcipotriene cream
Normalized name: Calcipotriene Cream
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene cream vs Vehicle (adverse reactions)
Study: 14601366
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 15 mg/kg intravenous upon anesthetic induction, every 4 hours during surgery, and every 8 hours for 48 hours post-surgery
Study: 2892988
Drug: Multivitamin/mineral supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin/mineral supplement administered for eight months
Study: 2892988
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for eight months
Study: 2892988
Drug: No tablets
Normalized name: caffeine Oral Tablet [No Doz]
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No tablets taken
Study: 28485023
Drug: High-dose rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rituximab (HD-R) 1000 mg/m2
Study: 28485023
Drug: Standard-dose rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-dose rituximab (SD-R) 375 mg/m2
Study: 28485023
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with ≤2 lines of treatment prior to SCT
Study: 26362286
Drug: Resveratrol 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 500 mg orally once daily (with dose escalation by 500‐mg increments every 13 weeks, ending with 1,000 mg twice daily)
Study: 23870300
Drug: Monthly ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly ranibizumab therapy
Study: 23870300
Drug: Quarterly ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Quarterly ranibizumab therapy
Study: 21608442
Drug: Myo-Inositol 2
Normalized name: myo-Inositol 2-dehydrogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-Inositol 2 g twice a day
Study: 21608442
Drug: D-chiro inositol
Normalized name: chiro-inositol, (+)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-chiro inositol 0.6 g twice a day
Study: 19366435
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of M-M-RvaxPro and VARIVAX
Study: 19366435
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of M-M-RvaxPro and VARIVAX